Fruquintinib as Post–Standard Third-Line Therapy in a Patient With mCRC Without Targetable Mutations: A Real-World Application of FRESCO Trial Principles

Sponsored by Takeda Oncology Please see Important Safety Information on page 11 and Full Prescribing Information. About the Patient SB is a 72-year-old male with […]

Molecular Residual Disease (MRD) Testing: Advancing Clinical Decision-Making in Breast Cancer

Abstract: Circulating tumor DNA (ctDNA) is emerging as a clinically meaningful biomarker across multiple solid tumors, including breast cancer. Advances in personalized, tumor-informed whole-genome sequencing have enabled […]

Clinical Response With Cabozantinib Plus Nivolumab, a First-Line Therapy in Advanced Renal Cell Carcinoma: A Clinical Case Report

In the Clinic . . . SH is a 47-year-old woman with a history of hypothyroidism and menopause who was diagnosed in March 2019 with Fuhrman […]